• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Ellex’s SLT technology launches in U.S.


Ellex Medical Lasers Ltd. announced that it has launched its proprietary selective laser trabeculoplasty (SLT) technology in the United States.

Adelaide, Australia-Ellex Medical Lasers Ltd. announced the launch of its proprietary selective laser trabeculoplasty (SLT) technology in the United States, with the official launch at this week's World Glaucoma Congress.

The launch comes following the expiration of a patent held by Massachusetts General Hospital (sub-licensed to Lumenis), which prevented Ellex from selling its SLT technology in the United States, the company said in a prepared statement.

SLT advanced laser therapy, which is non-invasive and non-thermal, stimulates a natural healing response in the eye to treat glaucoma.

“[SLT] also overcomes the compliance issues and side effects of anti-glaucoma medications, which have long plagued physicians and patients alike,” said Tom Spurling, chief executive officer of Ellex.

As a highly effective approach for first-line glaucoma treatment, SLT can also be used as an adjunct therapy with medications and as alternative therapy when medications or surgery fail. Ellex’s SLT technology platform is available in two product configurations: Tango SLT/YAG combination laser and Solo SLT laser.

For more articles in this issue of Ophthalmology Times eReport, click here.


To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.



Related Videos
© 2024 MJH Life Sciences

All rights reserved.